| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Sarraf Pasha | Director | C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON | /s/ Pasha Sarraf by Colin Sandercock, attorney-in-fact | 02 Jan 2026 | 0002059447 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CUE | Common Stock | Purchase | $1,308 | +4,229 | $0.3094 | 4,229 | 30 Dec 2025 | Direct | ||
| transaction | CUE | Common Stock | Purchase | $23,168 | +77,148 | +1824% | $0.3003 | 81,377 | 30 Dec 2025 | Direct | |
| transaction | CUE | Common Stock | Purchase | $27,597 | +86,947 | +107% | $0.3174 | 168,324 | 30 Dec 2025 | Direct | |
| transaction | CUE | Common Stock | Purchase | $24,325 | +78,116 | +46% | $0.3114 | 246,440 | 30 Dec 2025 | Direct | |
| transaction | CUE | Common Stock | Purchase | $23,349 | +77,417 | +31% | $0.3016 | 323,857 | 30 Dec 2025 | Direct |